Mithra Pharmaceuticals SA (OTCMKTS:MITPF – Get Rating) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totalling 171,200 shares, a decrease of 10.5% from the August 15th total of 191,200 shares. Based on an average trading volume of 300 shares, the short-interest ratio is currently 570.7 days.
Mithra Pharmaceuticals Stock Down 12.9 %
Shares of MITPF opened at $6.75 on Monday. Mithra Pharmaceuticals has a 1 year low of $6.75 and a 1 year high of $7.75. The business’s 50 day simple moving average is $12.10 and its 200-day simple moving average is $18.97.
Analyst Ratings Changes
Separately, Berenberg Bank decreased their price objective on Mithra Pharmaceuticals from €41.00 ($41.84) to €31.00 ($31.63) in a report on Wednesday, June 22nd.
About Mithra Pharmaceuticals
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment.
- Get a free copy of the StockNews.com research report on Mithra Pharmaceuticals (MITPF)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
Receive News & Ratings for Mithra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mithra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.